Tropical Diseases, Travel Medicine and Vaccines最新文献

筛选
英文 中文
Early intervention of 5% albumin shown superior control of vascular integrity and function compared to ringer's lactatein hospitalized adult with grade I & II Dengue hemorrhagic fever: a multicenter randomized controlled trial in Indonesia. 印度尼西亚一项多中心随机对照试验显示,与林格乳酸盐相比,5%白蛋白的早期干预能更好地控制血管完整性和功能。
IF 2.4
Tropical Diseases, Travel Medicine and Vaccines Pub Date : 2024-10-01 DOI: 10.1186/s40794-024-00230-3
Rika Bur, Suhendro Suwarto, Herdiman Theodorus Pohan, Joedo Prihartono, Alida Roswita Harahap, Beti Ernawati Dewi, Mohamad Sadikin, Andhika Rachman, Hadi Yusuf
{"title":"Early intervention of 5% albumin shown superior control of vascular integrity and function compared to ringer's lactatein hospitalized adult with grade I & II Dengue hemorrhagic fever: a multicenter randomized controlled trial in Indonesia.","authors":"Rika Bur, Suhendro Suwarto, Herdiman Theodorus Pohan, Joedo Prihartono, Alida Roswita Harahap, Beti Ernawati Dewi, Mohamad Sadikin, Andhika Rachman, Hadi Yusuf","doi":"10.1186/s40794-024-00230-3","DOIUrl":"10.1186/s40794-024-00230-3","url":null,"abstract":"<p><strong>Background: </strong>Dengue virus remains a major public health problem with one of the hallmark pathologies is the vascular leakage caused by endothelial dysfunction which can lead to Dengue Hemorrhagic Fever (DHF) manifestation. In the status quo, no specific therapy has been discovered but rather heavily relies on judicious and frequent monitoring of intravenous fluids administration. The current guideline has discussed the roles of fluid therapy during the Dengue Shock Syndrome (DSS) stage, however, administration of early fluid intervention for DHF grade I and II remains uncharted territory. In addition, the choice and timing of colloid administration remains underexplored. As one of the widely available colloids, 5% albumin has known physiological properties that potentially minimize plasma leakage. Therefore, this study aimed to evaluate the benefit of early intervention of 5% albumin in adults with DHF in the hope of preventing the lethal progression to DSS and further, shorten the length of stay (LOS) for patients.</p><p><strong>Methods: </strong>We conducted a multicenter, open-labeled, randomized controlled trial in Jakarta and Banten to compare the effect of early intervention with 5% albumin in adult patients with DHF compared to Ringer's Lactate (RL). Statistical analyses were conducted using unpaired t-test and Mann-Whitney for normally and abnormally distributed data respectively.</p><p><strong>Results: </strong>Adult patients with a diagnosis of DHF grade I and II that being hospitalized to receive the early intervention of 5% albumin had significantly lower levels of hemoconcentration 4, 12, and 24 h (p = 0.002, 0.001, 0.003, respectively), higher platelet counts 4 h (p = 0.036), higher serum albumin levels 48 h (p = 0.036), lower proteinuria 24 and 48 h post-albumin administration (p < 0.001, < 0.001, respectively), and shorter LOS (p < 0.001) when compared to the RL group.</p><p><strong>Conclusion: </strong>Early intervention of 5% albumin showed better control on vascular integrity and function compared to ringer lactate in hospitalized adults with grade I & II DHF, thus halting the progression of DHF into DSS and other related complications which leads to faster recovery and shorter length of stay.</p><p><strong>Trial registration: </strong>The study was registered to www.</p><p><strong>Clinicaltrial: </strong>gov with trial registration number NCT04076254, and registration date October 31st 2016.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"10 1","pages":"20"},"PeriodicalIF":2.4,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11443621/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142354556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A post-marketing study to evaluate the safety and immunogenicity of a quadrivalent influenza split-virion vaccine in elderly people aged 60 years and older. 一项针对 60 岁及以上老年人的上市后研究,旨在评估四价流感病毒裂解疫苗的安全性和免疫原性。
IF 2.4
Tropical Diseases, Travel Medicine and Vaccines Pub Date : 2024-09-15 DOI: 10.1186/s40794-024-00228-x
Zengqiang Kou, Xiaoyu Li, Ti Liu, Bei Fan, Wenqi An, Wenjue An, Mingan Dang, Ke Zhang, Jingning Tang, Nan Zhu, Ruowen Pan
{"title":"A post-marketing study to evaluate the safety and immunogenicity of a quadrivalent influenza split-virion vaccine in elderly people aged 60 years and older.","authors":"Zengqiang Kou, Xiaoyu Li, Ti Liu, Bei Fan, Wenqi An, Wenjue An, Mingan Dang, Ke Zhang, Jingning Tang, Nan Zhu, Ruowen Pan","doi":"10.1186/s40794-024-00228-x","DOIUrl":"https://doi.org/10.1186/s40794-024-00228-x","url":null,"abstract":"<p><strong>Background: </strong>Influenza remains a global public health concern. Understanding the vaccination-induced response in an aging population, which is susceptible and at high risk, is essential for disease prevention and control. Here, we report findings on the safety and immunogenicity of a quadrivalent influenza split-virion vaccine (15 µg/subtype/0.5 ml/dose) (hereinafter referred to as the \"quadrivalent influenza vaccine\") in a population aged ≥ 60 years.</p><p><strong>Methods: </strong>This open-label, pragmatic post-marketing trial enrolled 1399 older adults to receive one dose of an approved commercially available quadrivalent influenza vaccine manufactured by Hualan Biological Bacterin Inc. (hereinafter referred to as \"Hualan Bio\"). Participants with contraindications for the vaccine were excluded, while poor health condition was acceptable. All vaccinated subjects experienced adverse events collection within 30 days and serious adverse events within 180 days post-vaccination. 25% subjects, selected randomly, underwent venous blood sampling pre-vaccination and 30 days after post-vaccination, for detecting antibody titers against each subtype of influenza virus by hemagglutination inhibition assay. The incidences of adverse events and antibody titers against each subtype of influenza virus were statistically analyzed using SAS 9.4.</p><p><strong>Results: </strong>No grade 3 adverse reactions occurred within 30 days post-vaccination. The incidences of overall adverse reactions, local adverse reactions and systemic adverse reactions were 3.79%, 2.86% and 1.00%, respectively. No serious adverse reactions occurred within 180 days post-vaccination. There were 350 subjects who completed venous blood sampling pre-vaccination, among whom 348 subjects completed venous blood sampling at 30 days post-vaccination for immunogenicity assessment. With respect to hemagglutination inhibition antibodies against influenza viruses H1N1, H3N2, BV and BY subtypes, at 30 days post-vaccination, the seroconversion rates were 87.64%, 75.57%, 73.28% and 78.74%, respectively; the seropositive rates were 93.97%, 98.56%, 79.31% and 95.40%, respectively; and the geometric mean increase (GMI) in post-immunization/pre-immunization antibodies was 24.80, 7.26, 10.39 and 7.39, respectively.</p><p><strong>Conclusion: </strong>One 15 µg/subtype dose of the vaccine had a good safety profile and elicited favorable immunogenicity among subjects aged ≥ 60 years. The results of this study indicate that Hualan Bio quadrivalent influenza vaccine strike balance between safety and immunogenicity, supporting unnecessity to increase dosage or inoculation frequency for further enhancing immunogenicity.</p><p><strong>Trial registration: </strong>Registered on ClinicalTrials.gov.</p><p><strong>Registration number: </strong>NCT06334510. Registered on 28/03/2024 (retrospectively registered).</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"10 1","pages":"18"},"PeriodicalIF":2.4,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11402193/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142296300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Cardioembolic stroke in Chagas disease: unraveling the underexplored connection through a systematic review. 南美锥虫病引发的心栓塞性中风:通过系统回顾揭示未充分探索的关联。
IF 2.4
Tropical Diseases, Travel Medicine and Vaccines Pub Date : 2024-09-01 DOI: 10.1186/s40794-024-00227-y
Jorge Vásconez-González, Camila Miño, Juan S Izquierdo-Condoy, Camila Salazar-Santoliva, Andrés López-Cortés, Esteban Ortiz-Prado
{"title":"Cardioembolic stroke in Chagas disease: unraveling the underexplored connection through a systematic review.","authors":"Jorge Vásconez-González, Camila Miño, Juan S Izquierdo-Condoy, Camila Salazar-Santoliva, Andrés López-Cortés, Esteban Ortiz-Prado","doi":"10.1186/s40794-024-00227-y","DOIUrl":"10.1186/s40794-024-00227-y","url":null,"abstract":"<p><strong>Background: </strong>Chagas disease (CD), triggered by the Trypanosoma cruzi parasite, is originally endemic across Latin America, affecting millions. While cardiac complications are widely recognized, the association between CD and stroke remains underexplored. This systematic review aims to elucidate the relationship between CD and stroke, highlighting the cardioembolic origins of stroke in CD patients and assessing the elevated stroke risk compared to non-infected individuals.</p><p><strong>Methodology: </strong>Adhering to the PRISMA guidelines, we conducted a comprehensive search in PubMed and Scopus databases without date restrictions, including articles in both Spanish and English. This approach enabled the identification and analysis of relevant studies to understand the interplay between CD and stroke risk.</p><p><strong>Results: </strong>Our analysis of 25 selected studies indicates that strokes in CD patients predominantly arise from cardioembolic sources. The data underscore a significant increase in stroke risk among individuals infected with T. cruzi compared to uninfected counterparts. Additionally, CD patients face a higher stroke and mortality risk than those with other heart failure etiologies, irrespective of disease severity.</p><p><strong>Conclusion: </strong>The review establishes CD as a critical contributor to stroke incidence, emphasizing the need for heightened awareness and diagnosis of CD in stroke patients, particularly in regions with high CD prevalence. Recognizing the increased stroke risk associated with T. cruzi infection is crucial for developing targeted educational and preventive strategies in endemic areas.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"10 1","pages":"16"},"PeriodicalIF":2.4,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11366139/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142112378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Travellers with prosthetic limbs, a neglected population. A perspective on what travel health practitioners need to know. 装有假肢的旅行者,一个被忽视的群体。从旅行保健从业人员需要了解的角度出发。
IF 2.4
Tropical Diseases, Travel Medicine and Vaccines Pub Date : 2024-08-15 DOI: 10.1186/s40794-024-00226-z
Irmgard L Bauer, Vikranth H Nagaraja
{"title":"Travellers with prosthetic limbs, a neglected population. A perspective on what travel health practitioners need to know.","authors":"Irmgard L Bauer, Vikranth H Nagaraja","doi":"10.1186/s40794-024-00226-z","DOIUrl":"10.1186/s40794-024-00226-z","url":null,"abstract":"<p><strong>Background: </strong>The benefits of travel for the wellbeing of people of all ages and abilities are well known, though travellers with prostheses have so far been excluded. Limb loss, due to trauma, vascular disease, cancer, or infections requires a prosthesis for cosmesis and functionality. The life-changing event of losing a limb and the considerable psychological adjustment to accept an altered body image influence rehabilitation and self-management as well as the participation in social activities, such as sport and travel. The challenge of travel lies not only in transferring practical impediments encountered at home to another location; familiar coping strategies may require unexpected adjustments. After presenting background information on limb loss and prostheses, the purpose of this paper was to review literature on health advice for travellers with prosthetic limbs.</p><p><strong>Method: </strong>All major data bases were searched for peer-reviewed literature using a variation of keyword combinations around travel and prosthetics. Relevant journals were searched individually, and selected authors and university departments contacted. No evidence-based results were obtained. The search then moved to grey literature including documents from relevant organisations, professional bodies, government websites, manufacturers, airlines, prosthetic/physiotherapy clinics, sport organisations to approaching amputees, including veterans and athletes, directly.</p><p><strong>Result: </strong>The list of collated travel advice for people with artificial limbs relates to (1) trip preparation, (2) packing (especially considering the mechanical and/or electrical requirements of the prosthesis), (3) travelling by plane as the most covered mode of travel, and (4) navigating airports and airport security, which may be used by travel health practitioners while awaiting evidence-based guidelines.</p><p><strong>Conclusion: </strong>This is the first paper on travel with a prosthetic limb in any field, including travel medicine. Therefore, travel health practitioners have no evidence-based guidelines at their disposal required for high-quality care for this neglected population. Preliminary recommendations for clinical practice, advice for required updates in education, and suggestions for urgently needed research are provided to replace current hints and tips with evidence so that travellers with prostheses are no longer 'out on a limb'.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"10 1","pages":"14"},"PeriodicalIF":2.4,"publicationDate":"2024-08-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11325610/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141983316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A landscape review of malaria vaccine candidates in the pipeline. 疟疾疫苗候选项目概览。
IF 2.4
Tropical Diseases, Travel Medicine and Vaccines Pub Date : 2024-08-01 DOI: 10.1186/s40794-024-00222-3
Yusuf Amuda Tajudeen, Habeebullah Jayeola Oladipo, Sodiq Inaolaji Yusuff, Samuel O Abimbola, Muritala Abdulkadir, Iyiola Olatunji Oladunjoye, Abass Olawale Omotosho, Oluwaseyi Muyiwa Egbewande, Hameedat Damilola Shittu, Rashidat Onyinoyi Yusuf, Oluwatosin Ogundipe, Abdulbasit Opeyemi Muili, Abdullateef Opeyemi Afolabi, Salwa M A Dahesh, Marwa Ahmed Mahmoud Gameil, Mona Said El-Sherbini
{"title":"A landscape review of malaria vaccine candidates in the pipeline.","authors":"Yusuf Amuda Tajudeen, Habeebullah Jayeola Oladipo, Sodiq Inaolaji Yusuff, Samuel O Abimbola, Muritala Abdulkadir, Iyiola Olatunji Oladunjoye, Abass Olawale Omotosho, Oluwaseyi Muyiwa Egbewande, Hameedat Damilola Shittu, Rashidat Onyinoyi Yusuf, Oluwatosin Ogundipe, Abdulbasit Opeyemi Muili, Abdullateef Opeyemi Afolabi, Salwa M A Dahesh, Marwa Ahmed Mahmoud Gameil, Mona Said El-Sherbini","doi":"10.1186/s40794-024-00222-3","DOIUrl":"10.1186/s40794-024-00222-3","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Background: &lt;/strong&gt;Globally, malaria continues to pose a major health challenge, with approximately 247 million cases of the illness and 627,000 deaths reported in 2021. However, the threat is particularly pronounced in sub-Saharan African countries, where pregnant women and children under the age of five face heightened vulnerability to the disease. As a result, the imperative to develop malaria vaccines especially for these vulnerable populations, remains crucial in the pursuit of malaria eradication. However, despite decades of research, effective vaccine development faces technical challenges, including the rapid spread of drug-resistant parasite strains, the complex parasite lifecycle, the development of liver hypnozoites with potential for relapse, and evasion of the host immune system. This review aims to discuss the different malaria vaccine candidates in the pipeline, highlighting different approaches used for adjuvating these candidates, their benefits, and outcomes, and summarizing the progress of these vaccine candidates under development.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Method: &lt;/strong&gt;A comprehensive web-based search for peer-reviewed journal articles published in SCOPUS, MEDLINE (via PubMed), Science Direct, WHO, and Advanced Google Scholar databases was conducted from 1990 to May 2022. Context-specific keywords such as \"Malaria\", \"Malaria Vaccine\", \"Malaria Vaccine Candidates\", \"Vaccine Development\", \"Vaccine Safety\", \"Clinical Trials\", \"mRNA Vaccines\", \"Viral Vector Vaccines\", \"Protein-based Vaccines\", \"Subunit Vaccines\", \"Vaccine Adjuvants\", \"Vaccine-induced Immune Responses\", and \"Immunogenicity\" were emphatically considered. Articles not directly related to malaria vaccine candidates in preclinical and clinical stages of development were excluded.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Various approaches have been studied for malaria vaccine development, targeting different parasite lifecycle stages, including the pre-erythrocytic, erythrocytic, and sexual stages. The RTS, S/AS01 vaccine, the first human parasite vaccine reaching WHO-listed authority maturity level 4, has demonstrated efficacy in preventing clinical malaria in African children. However, progress was slow in introducing other safe, and feasible malaria vaccines through clinical trials . Recent studies highlight the potential effectiveness of combining pre-erythrocytic and blood-stage vaccines, along with the advantages of mRNA vaccines for prophylaxis and treatment, and nonstructural vaccines for large-scale production.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Malaria vaccine candidates targeting different lifecycle stages of the parasite range from chemoprophylaxis vaccination to cross-species immune protection. The use of a multi-antigen, multi-stage combinational vaccine is therefore essential in the context of global health. This demands careful understanding and critical consideration of the long-term multi-faceted interplay of immune interference, co-dominance, complement","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"10 1","pages":"19"},"PeriodicalIF":2.4,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11293096/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141861040","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Characterizing zero-dose and under-vaccinated children among refugees and internally displaced persons in the Democratic Republic of Congo. 刚果民主共和国难民和境内流离失所者中接种疫苗次数为零和不足的儿童的特征。
IF 2.4
Tropical Diseases, Travel Medicine and Vaccines Pub Date : 2024-07-15 DOI: 10.1186/s40794-024-00225-0
Marcellin Mengouo Nimpa, Aimé Cikomola Mwana-Wabene, John Otomba, Jean-Crispin Mukendi, M Carolina Danovaro-Holliday, Franck-Fortune Mboussou, Dieudonné Mwamba, Leandre Kambala, Dolla Ngwanga, Cedric Mwanga, Sume Gerald Etapelong, Issaka Compaoré, Moise Désiré Yapi, Daniel Katuashi Ishoso
{"title":"Characterizing zero-dose and under-vaccinated children among refugees and internally displaced persons in the Democratic Republic of Congo.","authors":"Marcellin Mengouo Nimpa, Aimé Cikomola Mwana-Wabene, John Otomba, Jean-Crispin Mukendi, M Carolina Danovaro-Holliday, Franck-Fortune Mboussou, Dieudonné Mwamba, Leandre Kambala, Dolla Ngwanga, Cedric Mwanga, Sume Gerald Etapelong, Issaka Compaoré, Moise Désiré Yapi, Daniel Katuashi Ishoso","doi":"10.1186/s40794-024-00225-0","DOIUrl":"10.1186/s40794-024-00225-0","url":null,"abstract":"<p><strong>Background: </strong>The Democratic Republic of Congo (DRC) has one of the highest numbers of un and under-vaccinated children as well as number of refugees and internally displaced persons (IDPs) in the world. This study aims to determine and compare the proportion and characteristics of zero-dose (ZD) and under-vaccinated (UV) children among refugees and IDPs in the DRC, as well as the reasons for incomplete vaccination schedules.</p><p><strong>Methods: </strong>Data from a rolling vaccination coverage survey conducted from September 10, 2022, to July 03, 2023, among refugees and IDPs in 12 provinces of the DRC. ZD was defined as a child aged 12-23 months who had not received any dose of pentavalent vaccine DTP-Hib-Hep B (by card or recall) and UV as a child who had not received the third dose of pentavalent vaccine. The proportions of non and under-vaccination and the associated factors using a logistic regression model are presented for ZD and UV children. The reasons for non-vaccination of these children are described using the WHO-Immunization behavioral and social-drivers-conceptual framework and compared using Pearson's Chi2 test.</p><p><strong>Results: </strong>Of 692 children aged 12 to 23 months included in the analysis, 9.3% (95% CI: 7.2-11.7%) were ZD and 40.9% (95% CI: 95%: 37.2-44.6%) UV. The Penta1/Penta3 drop-out rate was 34.9%. After adjustment, ZD children had a significant history of home or road birth. And UV children were significantly associated with mothers/caregivers being under 40, uneducated, farmers, ranchers, employed, rural residents, as well as with home or road births. Reasons linked to people's perceptions and feelings were cited much more often for ZD (50.0%) than for UV (38.3%). Those related to social reasons were cited much more often by ZD (40.6%) than by UV (35.7%). Reasons related to \"programmatic and practical issues\" were cited less for ZD (90.5%) than for UV (97.1%).</p><p><strong>Conclusions: </strong>ZD and UV children represent significant proportions in refugee and IDPs sites in the DRC. However, the proportion of ZD is less than for the entire country, while the proportion of UV is comparable, reflected in a very high drop-out rate. Similarly to studies in the general population in DRC, the reasons for ZD children were mainly linked to challenges in caregiver motivation to vaccinate, while for UV children, they were more often linked to pro-grammatic and practical problems of the health system.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"10 1","pages":"17"},"PeriodicalIF":2.4,"publicationDate":"2024-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11247746/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141617136","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trend of pulmonary tuberculosis and rifampicin-resistance among tuberculosis presumptive patients in Central Tigray, Ethiopia; 2018 -2023: a six-year retrospective study. 2018-2023年埃塞俄比亚提格雷中部肺结核推定患者的肺结核和利福平耐药性趋势:一项为期六年的回顾性研究。
IF 2.4
Tropical Diseases, Travel Medicine and Vaccines Pub Date : 2024-07-01 DOI: 10.1186/s40794-024-00224-1
Guesh Gebremariam, Mulugeta Kiros, Selemun Hagos, Haftom Hadush, Amaha Gebremichael, Gebretsadkan Gebrekirstos, Aregawi Tesfay, Teumelsan Gebrewahid, Tesfay Berihu, Brhane Gebremariam
{"title":"Trend of pulmonary tuberculosis and rifampicin-resistance among tuberculosis presumptive patients in Central Tigray, Ethiopia; 2018 -2023: a six-year retrospective study.","authors":"Guesh Gebremariam, Mulugeta Kiros, Selemun Hagos, Haftom Hadush, Amaha Gebremichael, Gebretsadkan Gebrekirstos, Aregawi Tesfay, Teumelsan Gebrewahid, Tesfay Berihu, Brhane Gebremariam","doi":"10.1186/s40794-024-00224-1","DOIUrl":"10.1186/s40794-024-00224-1","url":null,"abstract":"<p><strong>Background: </strong>Tuberculosis (TB) is a major public health concern in the developing countries. Moreover, the emergence of multidrug-resistant tuberculosis is challenging. However, there are no organized data on the trends of pulmonary tuberculosis and rifampicin-resistant Mycobacterium tuberculosis in the study area.</p><p><strong>Methods: </strong>A retrospective cross-sectional study was conducted to fill the information gap in Central Tigray at St. Mary General Hospital between 2018 and 2023. Data were collected from the GeneXpert™ tuberculosis registration logbooks using standard checklists and analyzed using Statistical Package for Social Science version 22. After performing logistic regression, a p-value < 0.05 with a corresponding 95% confidence interval was considered statistically significant. Moreover, chi square test for trend was performed to assess the percentage of annual detection of pulmonary tuberculosis and rifampicin-resistant Mycobacterium tuberculosis during the study years.</p><p><strong>Result: </strong>Presumptive pulmonary tuberculosis patients with complete data (n = 3696) were included in the study. The overall prevalence of pulmonary tuberculosis was 11.7%, of which 8.1% were resistant to rifampicin. The study revealed that the incidence of pulmonary tuberculosis has been increasing, mainly in the recent four years. Likewise, an increase in rifampicin-resistant Mycobacterium tuberculosis was observed with considerable fluctuations. Age, human immunodeficiency virus infection, and presumptive rifampicin-resistant Mycobacterium tuberculosis infection were significantly associated with the presence of pulmonary tuberculosis. Moreover, pulmonary tuberculosis was more prevalent among participants in the productive-age group.</p><p><strong>Conclusion: </strong>Although there have been fluctuations, an increasing of pulmonary tuberculosis and rifampicin-resistant Mycobacterium tuberculosis has been observed in recent years. Hence, prevention and treatment strategies for tuberculosis should be strengthened to alleviate the burden of pulmonary tuberculosis and rifampicin-resistant Mycobacterium tuberculosis in the study area.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"10 1","pages":"15"},"PeriodicalIF":2.4,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11215829/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141471005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the utilization and perceptions of pre-travel health consultations in primary care settings in Saudi Arabia: a cross-sectional study. 探索沙特阿拉伯初级保健机构对旅行前健康咨询的利用和看法:一项横断面研究。
IF 3.1
Tropical Diseases, Travel Medicine and Vaccines Pub Date : 2024-06-15 DOI: 10.1186/s40794-024-00223-2
Naheel A AlAmer, Amani M AlQarni
{"title":"Exploring the utilization and perceptions of pre-travel health consultations in primary care settings in Saudi Arabia: a cross-sectional study.","authors":"Naheel A AlAmer, Amani M AlQarni","doi":"10.1186/s40794-024-00223-2","DOIUrl":"10.1186/s40794-024-00223-2","url":null,"abstract":"<p><strong>Background: </strong>International travel exposes individuals to diverse health risks, necessitating proactive pre-travel health preparations. Saudi Arabia has witnessed increased outbound travel. This study addresses a critical gap in knowledge by investigating the utilization and perceptions of pre-travel health consultations among adults in the Eastern Province of Saudi Arabia.</p><p><strong>Methods: </strong>This cross-sectional study surveyed patients at the Family and Community Medicine Center of Imam Abdulrahman Bin Faisal University during January 2024 to explore perceptions of pre-travel health consultations among the Saudi Arabian population. Adults aged 18 years or older in the waiting area were invited to complete a self-administered questionnaire.</p><p><strong>Results: </strong>Of the 772 participants, 624 (80.8%) engaged in international travel within the last year. However, 593 (76.8%) had never sought pre-travel health consultations. Age, gender, and education level significantly influenced the pursuit of pre-travel health advice, with older individuals, females, and those with higher educational attainment more likely to seek consultations. Participants perceived vaccination recommendations (597, 77.4%) and disease prevention information (678, 87.8%) as crucial parts of pre-travel health consultations. However, barriers to seeking advice included perceived low risk (445, 74.8%), lack of awareness (215, 36.3%), time constraints (128, 21.6%), and cost concerns (92, 15.5%).</p><p><strong>Conclusion: </strong>The low prevalence of pre-travel health consultations among travelers highlights the need for targeted educational campaigns and the integration of travel health services into primary healthcare. Addressing the identified barriers and leveraging preferred information sources are crucial steps towards enhancing the uptake of pre-travel health consultations, ultimately improving the health and safety of international travelers from the region.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"10 1","pages":"13"},"PeriodicalIF":3.1,"publicationDate":"2024-06-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11179328/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141321716","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Tetanus- a case report highlighting the challenges in diagnosis and treatment. 破伤风--病例报告凸显诊断和治疗的挑战。
IF 3.1
Tropical Diseases, Travel Medicine and Vaccines Pub Date : 2024-06-01 DOI: 10.1186/s40794-024-00220-5
Menno Boer, Martijn de Voogd, Nicolasine Diana Niemeijer, Lonneke van Hoeven
{"title":"Tetanus- a case report highlighting the challenges in diagnosis and treatment.","authors":"Menno Boer, Martijn de Voogd, Nicolasine Diana Niemeijer, Lonneke van Hoeven","doi":"10.1186/s40794-024-00220-5","DOIUrl":"10.1186/s40794-024-00220-5","url":null,"abstract":"<p><p>Tetanus has become an increasingly rare infectious disease due to the development of successful vaccination programs in the mid-20th century. In resource-rich countries, mainly unvaccinated or partly vaccinated risk groups are affected, whereas tetanus still remains prevalent in resource-limited countries. The decreasing incidence in developed countries has hindered clinical trials evaluating the best treatment modalities for tetanus infections. Current guidelines are based on a small number of studies and case reports. So far, these studies have shown potential benefits of treating tetanus infections with benzodiazepines, magnesium sulfate and baclofen. Additionally, several treatments have been shown to be useful in stabilizing and supporting patients with tetanus. However, each treatment modality has limitations, from negative side effects to logistical challenges, especially in developing countries. Therefore, further knowledge is required to evaluate the best use of each treatment and to further optimize patient care. This knowledge can contribute to the reduction of the burden of disease in countries where tetanus remains prevalent and where resources are limited, though vaccination is the most effective method to achieve this. This case report describes the treatment of a Dutch patient with tetanus infection and illustrates the role of benzodiazepines as well as other key aspects of treating patients with tetanus.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"10 1","pages":"10"},"PeriodicalIF":3.1,"publicationDate":"2024-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11143707/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141187060","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Blood smears examination and prevalence of malaria in Addis Zemen Town, Northwest Ethiopia (2013-2021): a retrospective study. 埃塞俄比亚西北部亚的斯亚贝巴泽门镇的血液涂片检查和疟疾流行情况(2013-2021 年):一项回顾性研究。
IF 2.4
Tropical Diseases, Travel Medicine and Vaccines Pub Date : 2024-05-15 DOI: 10.1186/s40794-024-00219-y
Tilahun Adugna, Lamesgin Zelalem, Gedafaw Alelign
{"title":"Blood smears examination and prevalence of malaria in Addis Zemen Town, Northwest Ethiopia (2013-2021): a retrospective study.","authors":"Tilahun Adugna, Lamesgin Zelalem, Gedafaw Alelign","doi":"10.1186/s40794-024-00219-y","DOIUrl":"10.1186/s40794-024-00219-y","url":null,"abstract":"<p><strong>Introduction: </strong>In Ethiopia, malaria is one of the major public health and socioeconomic problems, though tremendous efforts have been made. Currently, the country has a plan to eliminate malaria by 2030. To achieve this plan, epidemiological studies associated with malaria prevalence with gender, age groups, species types, and seasons are essential. Therefore, the aim of this study was to assess the prevalence of malaria from 2013 to 2021 in Addis Zemen town, Northwest Ethiopia.</p><p><strong>Methods: </strong>A retrospective study was conducted at assess the trend of malaria prevalence over the last nine years using recorded blood smear reports in the laboratory logbook from governmental health institutions. Trends in malaria cases and the proportion of genders, age groups, species, and seasons over time were compared. The data were analyzed using the SPSS-23 software package.</p><p><strong>Results: </strong>The overall malaria prevalence between 2013 and 2021 was 10.4%. From all confirmed cases, the minimum and maximum prevalence of malaria cases were recorded in 2018 (2%) and 2016 (33.2%) years, respectively. The infectious rate of males (59.3%) was significantly higher than that of females (40.7%) (p < 0.0001). In all survey periods, all age groups were infected by malaria parasites; the majority of the cases were between 15 and 45 years (57%) older than others. Statistically, a greater proportion of P. falciparum (80.1%) was recorded than P. vivax (18.5%) (p < 0.0001). Malaria cases were occurring throughout each month. The relative highest peaks of total malaria cases were observed during the months of September, October, and November. Seasonally, the highest infection rate was observed during spring (40.20%) compared to other seasons.</p><p><strong>Conclusions: </strong>In conclusion, the study revealed that malaria transmission remained high, which affected males more than females and potentially reproductive ages. Two of the most important Plasmodium species were identified and found during all reviewed months and years, though P. falciparum was the most prevalent. Hence, the problem can be alleviated by using season-based long-lasting insecticide treated nets, regularly overseeing ongoing irrigation activity, overseeing the reduction of the water level of the Sheni River, health education, and providing immediate patient treatment.</p>","PeriodicalId":23303,"journal":{"name":"Tropical Diseases, Travel Medicine and Vaccines","volume":"10 1","pages":"12"},"PeriodicalIF":2.4,"publicationDate":"2024-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11095033/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140923457","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信